Table 1.
Participant demographics and clinical pathological results
| Parameters | Responder (n = 34) | Non-responder (n = 28) | p value |
|---|---|---|---|
| Age at enrollment (years)a | 52.8 ± 11.3 | 53.1 ± 16.3 | 0.72 |
| Pathologic type | 0.03* | ||
| Invasive ductal carcinoma | 29 (63.0) | 17 (37.0) | |
| Invasive lobular carcinoma | 4 (50.0) | 4 (50.0) | |
| Invasive mammary carcinoma with mixed ductal and lobular features | 1 (12.5) | 7 (87.5) | |
| Pathologic grade | 0.05 | ||
| I/II | 11 (39.3) | 17 (60.7) | |
| III | 23 (67.7) | 11 (32.3) | |
| Estrogen receptor status | 0.17 | ||
| Positive | 20 (47.6) | 22 (52.4) | |
| Negative | 14 (70.0) | 6 (30.0) | |
| Progesterone receptor status | 0.44 | ||
| Positive | 20 (50.0) | 20 (50.0) | |
| Negative | 14 (63.6) | 8 (36.4) | |
| HER2 status | 0.19 | ||
| Positive | 15 (68.2) | 7 (31.8) | |
| Negative | 19 (47.5) | 21 (52.5) | |
| Ki-67 index (%) | |||
| Measureda | 40.1 ± 25.1 (46.7) | 27.0 ± 20.1 (53.3) | 0.05 |
| Data missing | (76.5) | (23.5) | |
| Subtype | |||
| ER+ tumor types | 0.03* | ||
| Luminal A | 1 (12.5) | 7 (87.5) | |
| Luminal B (HER2-) | 8 (47.1) | 9 (52.9) | |
| Luminal B (HER2+) | 11 (68.8) | 5 (31.2) | |
| Other tumor types | 0.92 | ||
| HER2+ | 4 (66.7) | 2 (33.3) | |
| TN | 9 (81.8) | 2 (18.2) | |
| Data missing | 1 (25.0) | 3 (75.0) | |
Data in parentheses are percentages
ER estrogen receptor, HER2 human epidermal growth factor receptor 2, TN triple-negative
aData are mean ± standard deviation
*p < 0.05; the difference is statistically significant